By
Adrianne Appel2022-10-11T15:45:00
The high price on Biogen’s $900 million settlement for False Claims Act (FCA) violations shows the government is still keenly interested in cases of illegal kickbacks in physician referrals, experts and attorneys said.
“It’s a wake-up call to companies that they need to remain diligent in their compliance in this area,” said David Colapinto, partner at whistleblower law firm Kohn, Kohn & Colapinto.
Last month, Biogen finalized settlement of the lawsuit, after years of litigation by former employee Michael Bawduniak. Bawduniak, represented by boutique law firm Greene, alleged the company paid illegal kickbacks to doctors to induce them to prescribe Biogen’s multiple sclerosis drugs.
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
2024-12-03T17:48:00Z By Aaron Nicodemus
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission after self-reporting that it failed to disclose material information about two cancer drugs to investors.
2022-09-27T19:04:00Z By Adrianne Appel
Biogen finalized a $900 million settlement concerning alleged kickbacks it paid to doctors to induce them to prescribe the company’s drugs and not those of its competitors.
2022-08-24T19:06:00Z By Aaron Nicodemus
Essilor, a manufacturer and distributor of optical lenses and equipment, will pay $22 million to settle allegations it paid kickbacks to spur sales in violation of the False Claims Act.
2026-03-19T21:08:00Z By Aaron Nicodemus
The U.S. Securities and Exchange Commission’s Mark Uyeda told an audience of investment advisers that the SEC will no longer prioritize stand-alone enforcement actions for violations of the SEC’s rules on off-channel communications.
2026-03-17T21:22:00Z By Oscar Gonzalez
Adobe agreed to a $150 million settlement with the U.S. Department of Justice over accusations that it concealed software termination fees and made it difficult for customers to cancel.
2026-03-13T21:06:00Z By Neil Hodge
New powers granted to the U.K.’s main competition watchdog will result in greater scrutiny, tougher enforcement, and a stark warning for companies to review their sales and marketing promotions—especially since some practices have been pushed firmly into the spotlight thanks to legislation that came into effect last year.
Site powered by Webvision Cloud